Published in J Neurol Neurosurg Psychiatry on December 01, 2002
fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology (2005) 3.22
Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response. Neurobiol Aging (2006) 1.58
Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx (2005) 1.58
Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.37
Prediction of cognitive decline in healthy older adults using fMRI. J Alzheimers Dis (2010) 1.12
FMRI of working memory in patients with mild cognitive impairment and probable Alzheimer's disease. Eur Radiol (2005) 1.09
Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI. J Magn Reson Imaging (2011) 1.08
The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol Biochem Behav (2011) 1.07
Cholinergic enhancement of episodic memory in healthy young adults. Psychopharmacology (Berl) (2005) 1.06
Potential of functional MRI as a biomarker in early Alzheimer's disease. Neurobiol Aging (2011) 0.99
Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS. NMR Biomed (2006) 0.99
Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transm (Vienna) (2005) 0.91
Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials. Arch Neurol (2011) 0.91
Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions. Eur Radiol (2007) 0.90
Donepezil improves episodic memory in young individuals vulnerable to the effects of sleep deprivation. Sleep (2009) 0.87
Cholinergic enhancement eliminates modulation of neural activity by task difficulty in the prefrontal cortex during working memory. J Cogn Neurosci (2008) 0.84
Cholinergic modulation of visual working memory during aging: a parametric PET study. Brain Res Bull (2009) 0.84
Cholinergic enhancement of functional networks in older adults with mild cognitive impairment. Ann Neurol (2013) 0.80
Retinal Structures and Visual Cortex Activity are Impaired Prior to Clinical Vision Loss in Glaucoma. Sci Rep (2016) 0.79
Examining brain-cognition effects of ginkgo biloba extract: brain activation in the left temporal and left prefrontal cortex in an object working memory task. Evid Based Complement Alternat Med (2011) 0.79
Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy. Psychopharmacology (Berl) (2015) 0.78
Donepezil effects on hippocampal and prefrontal functional connectivity in Alzheimer's disease: preliminary report. J Alzheimers Dis (2012) 0.77
Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease. Neuropsychiatr Dis Treat (2008) 0.76
Cholinergic Enhancement of Brain Activation in Mild Cognitive Impairment during Episodic Memory Encoding. Front Psychiatry (2013) 0.76
Individuals at risk for Alzheimer's disease show differential patterns of ERP brain activation during odor identification. Behav Brain Funct (2012) 0.75
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clin Interv Aging (2017) 0.75
Time related effects on functional brain connectivity after serotonergic and cholinergic neuromodulation. Hum Brain Mapp (2016) 0.75
An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine. Br J Clin Pharmacol (2017) 0.75
Visualizing Hyperactivation in Neurodegeneration Based on Prefrontal Oxygenation: A Comparative Study of Mild Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls. Front Aging Neurosci (2017) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 47.72
Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage (2002) 29.63
The fusiform face area: a module in human extrastriate cortex specialized for face perception. J Neurosci (1997) 22.73
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology (1997) 8.50
A parametric study of prefrontal cortex involvement in human working memory. Neuroimage (1997) 5.34
In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage (2001) 3.87
Functional MRI studies of spatial and nonspatial working memory. Brain Res Cogn Brain Res (1998) 3.45
Face encoding and recognition in the human brain. Proc Natl Acad Sci U S A (1996) 2.31
Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science (2000) 2.28
Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol (1999) 2.13
Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neurosci Lett (2000) 1.77
Functional MRI detection of pharmacologically induced memory impairment. Proc Natl Acad Sci U S A (2001) 1.74
Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy (2000) 1.14
A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol (1999) 1.09
Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J Neurol Sci (2000) 1.05
Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging (1998) 0.97
Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A (2006) 19.60
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Reduced resting-state brain activity in the "default network" in normal aging. Cereb Cortex (2007) 5.28
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry (1992) 4.16
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology (2010) 3.98
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. Brain (2008) 3.36
Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage (2004) 3.25
A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci (1993) 3.16
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol (1999) 2.92
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology (2007) 2.88
Cortical lesions in multiple sclerosis. Brain (1999) 2.83
Incident lacunes influence cognitive decline: the LADIS study. Neurology (2011) 2.81
A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage (2003) 2.67
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl (2000) 2.56
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol (2007) 2.47
Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology (2008) 2.41
Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry (2002) 2.41
Prevalence and severity of microbleeds in a memory clinic setting. Neurology (2006) 2.29
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology (2011) 2.26
EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol (2010) 2.21
Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology (2006) 2.19
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 2.17
Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology (2011) 2.17
Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology (2012) 2.16
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
Regional DTI differences in multiple sclerosis patients. Neuroimage (2008) 2.03
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol (1999) 1.99
Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry (2000) 1.97
CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging (2006) 1.91
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. Eur J Neurol (2000) 1.89
Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology (2009) 1.88
Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology (2010) 1.88
Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol (1995) 1.87
Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology (1995) 1.86
Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain (2008) 1.84
CT and MRI rating of white matter lesions. Cerebrovasc Dis (2002) 1.83
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78
Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke (2003) 1.78
Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neurosci Lett (2000) 1.77
White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. Brain (1992) 1.77
A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76
Familial aggregation in frontotemporal dementia. Neurology (1998) 1.76
The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia. J Neurol Neurosurg Psychiatry (2004) 1.73
MR venography of multiple sclerosis. AJNR Am J Neuroradiol (2000) 1.72
The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology (2006) 1.71
[Acute subdural hematoma following minor head injury]. Ned Tijdschr Geneeskd (1992) 1.69
Hippocampal atrophy in Alzheimer disease: age matters. Neurology (2006) 1.66
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: a 3-year follow-up of the LADIS study cohort. J Neurol Sci (2011) 1.66
Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia (2006) 1.66
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
Cardiovascular and Interventional Radiological Society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency. Cardiovasc Intervent Radiol (2010) 1.66
Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology (2004) 1.65
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol (1996) 1.64
Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer's disease. Neuroimage (2006) 1.64
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology (1995) 1.63
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology (1997) 1.60
Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types. AJNR Am J Neuroradiol (2009) 1.60
Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology (1998) 1.58
Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology (2007) 1.57
Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology (2011) 1.56
Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain (2001) 1.56
Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. Hippocampus (2000) 1.55
Functional MR imaging in Alzheimer's disease during memory encoding. AJNR Am J Neuroradiol (2001) 1.54
Circadian rest-activity rhythm disturbances in Alzheimer's disease. Biol Psychiatry (1996) 1.54
Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.53
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
The predictive value of 3D time-of-flight MR angiography in assessment of brain arteriovenous malformation obliteration after radiosurgery. AJNR Am J Neuroradiol (2011) 1.53
Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain (1998) 1.52
Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. AJNR Am J Neuroradiol (2008) 1.50
Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology (1996) 1.50
Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography. Ann Surg (1999) 1.49